Isoquercitrin (Isoquercetin, Quercetin-3-O-glucoside)
Isoquercitrin, also sold as isoquercetin, is quercetin with one glucose attached (quercetin-3-O-glucoside). For supplements it is made from rutin by removing one of its sugars. In volunteers it was absorbed quickly, with blood quercetin peaking about 37 minutes after a dose, although a higher blood level is not itself a health outcome. Human trials of plain isoquercitrin are few: single doses of 50 to 400 mg did not improve an artery widening test or blood pressure in healthy adults, and high doses lowered blood clotting markers in patient studies, while the one placebo-controlled patient trial found no change in its main outcome. Most trials often quoted for isoquercitrin tested EMIQ, San-Ei Gen's enzymatically modified isoquercitrin with extra glucose units, or related quercetin glycosides from the same company. Those results are summarized here as other-product references; see the EMIQ page.
Benefits
Absorbed more readily than plain quercetin
In 9 healthy adults, a single dose of pure isoquercitrin was absorbed quickly, with blood quercetin peaking about 37 minutes later. A review of 31 human studies found the EMIQ type, with extra glucose units, gave about 2 times the uptake of isoquercitrin and about 20 times that of plain quercetin powder. Quercetin spread through shallot skin was absorbed better than shallot glucosides. Blood levels show uptake, not a health benefit.
Artery function after single doses
In 15 healthy adults, single doses of 50 to 400 mg of isoquercitrin raised blood quercetin but did not improve flow-mediated dilation, a test of how well the arm artery widens, or blood pressure at any dose. In a separate maker-funded study of a related product, one dose of EMIQ raised flow-mediated dilation by 1.8 points versus placebo 1.5 hours later without changing blood pressure. See the EMIQ page.
Eye symptom scores in two pollen season trials (EMIQ)
Two small placebo-controlled Japanese trials gave about 100 mg EMIQ a day for 8 weeks to adults with cedar pollen allergy (20 and 24 people). An eye symptom score over the study was lower than on placebo in each, but neither abstract names a primary outcome or a correction for the many scores compared, and nose symptoms and blood IgE did not differ significantly. Five co-authors of both trials were from the maker. See the EMIQ page.
Leg muscle mass with whey protein (EMIQ)
In 39 university American football players, 20 g of whey with 42 mg EMIQ six days a week for 4 months raised lower limb muscle mass by about 0.93 kg versus 0.26 kg with whey alone, one of two stated primary outcomes. Whole-body lean mass, the other, did not differ, nor did body weight or fat mass. The food company Morinaga, which prepared the supplements, funded the trial and employed four of its seven authors. See the EMIQ page.
Muscle strength with training (related quercetin glycosides)
These trials used San-Ei Gen quercetin glycosides made by the same enzyme route but not named EMIQ in the papers. In 26 older adults who completed the trial (30 were randomized), 200 mg a day for 6 weeks of training raised knee extension force about 15% versus 5% on placebo, the primary outcome, without a change in muscle mass. In a company-funded 24-week trial, thigh muscle size, the primary outcome, did not change. See the EMIQ page.
Blood antioxidant markers with protein powder (EMIQ)
After 4 months of whey with 42 mg EMIQ, athletes had a higher ratio of blood antioxidant capacity to oxidative stress than with whey alone, a secondary outcome. In a 7-day crossover of 9 adults, 42 mg EMIQ added to soy protein also lowered oxidative stress readings. Both trials were run with the food company Morinaga, and these are lab markers, not health outcomes. See the EMIQ page.
Reaction time in adults aged 60 to 75 (EMIQ drink)
In 80 healthy adults aged 60 to 75, a daily drink with 110 mg of EMIQ-based quercetin glycosides for 40 weeks did not differ from placebo on the main outcome, the MMSE cognitive screening score, which rose in both groups. Reaction time on a computer test, a secondary outcome, improved more than on placebo, and brain blood flow did not differ. Three of the five authors worked at Suntory, which supplied the drinks. See the EMIQ page.
Mechanism of action
Glucose units help quercetin reach the blood
Plain quercetin dissolves poorly in the gut. With one glucose attached, isoquercitrin was absorbed quickly in volunteers, with blood quercetin peaking about 37 minutes after a dose. EMIQ is more water soluble again and was absorbed more efficiently than isoquercitrin or rutin, with the same pattern of quercetin breakdown products in the blood.
Effects on blood clotting proteins
Isoquercetin blocks protein disulfide isomerase, an enzyme involved in clot formation. In a cancer patient study, 500 to 1,000 mg/day lowered platelet-dependent thrombin generation and 1,000 mg/day lowered D-dimer. In a placebo-controlled sickle cell study, 1,000 mg/day lowered whole-blood clotting and platelet aggregation from baseline, though the main outcome, soluble P-selectin, did not differ from placebo. This is the reason for caution with blood thinners.
How the artery effect arises is unclear
Quercetin is proposed to support blood vessel function through nitric oxide. In both single-dose artery studies, however, blood markers of nitric oxide did not change, so the reason for the flow-mediated dilation result in the EMIQ study is not known.
Clinical trials
Other-product reference: this trial tested EMIQ, a separate product with its own page, not plain isoquercitrin. Randomized, controlled crossover trial (ACTRN12617001202358): one dose of 4.89 mg EMIQ per kg body weight (2 mg quercetin equivalent per kg) or a maltodextrin placebo in a flavored drink with a standard breakfast, visits at least 7 days apart; flow-mediated dilation was the primary endpoint; EMIQ prepared by and study funded by San-Ei Gen F.F.I., which the paper says had no role in design, analysis or writing (Bondonno et al. 2020, Br J Nutr)
25 adults in Australia (12 men, 13 women) with at least one cardiovascular risk factor, such as systolic blood pressure of 120 to 160 mmHg, raised fasting glucose or cholesterol, or a large waist.
Flow-mediated dilation 1.5 hours after the dose, the primary endpoint, was 1.80 percentage points higher after EMIQ than after placebo (95% CI 0.23 to 3.37; P = 0.025), and plasma quercetin metabolites were higher (P < 0.001). Blood pressure over 80 minutes (systolic P = 0.916), arterial stiffness, cognitive function and oxidative stress and nitric oxide markers did not differ. Only one dose was tested, and the study was powered only for the primary outcome.
Randomized, controlled crossover dose-response study of 0, 50, 100, 200 or 400 mg quercetin-3-O-glucoside (isoquercitrin), each given on a separate visit at least 1 week apart (Bondonno et al. 2016, Am J Clin Nutr)
15 healthy men and women.
Blood quercetin rose with dose, but there was no improvement in flow-mediated dilation or blood pressure, and no change in nitric oxide markers, at any dose. The primary outcomes were null.
Other-product reference: this trial tested EMIQ, a separate product with its own page, not plain isoquercitrin. Randomized, double-blind, placebo-controlled parallel-group trial: EMIQ (two capsules daily of 100 mg, as the abstract words it) or placebo for 8 weeks during the pollen season; five of the 17 authors (Koyanagi, Kai, Shimizu, Moriwaki, Suzuki) are listed at San-Ei-Gen F.F.I.; funding is not stated in the abstract (Kawai et al. 2009, Int Arch Allergy Immunol)
20 adults with Japanese cedar pollen allergy.
Over the whole study, total eye symptom and eye itching scores were lower with EMIQ than placebo (p < 0.05). Total symptom score was lower only in weeks 4 to 5, while nasal (p = 0.06), eye congestion (p = 0.08) and daily activity (p = 0.08) scores only trended lower. Serum IgE and cytokines did not fall significantly; oxidized LDL and the chemokine TARC fell. The abstract does not name a primary outcome or a correction for the many scores compared.
Other-product reference: this trial tested EMIQ, a separate product with its own page, not plain isoquercitrin. Randomized, double-blind, placebo-controlled parallel-group trial: 100 mg EMIQ a day or placebo for 8 weeks, starting 4 weeks before pollen release; nearly the same author list as the in-season trial, including the five co-authors listed there at San-Ei-Gen F.F.I. (Hirano et al. 2009, Allergol Int)
24 adults with Japanese cedar pollen allergy.
Over the whole study, the combined eye symptom plus medication score was lower with EMIQ (p < 0.05), and eye symptom and eye congestion scores were lower in weeks 5 to 6. Eye itching (p = 0.09) and tearing (p = 0.07) only trended lower, nasal symptoms did not differ, and serum IgE did not fall significantly, while blood quercetin rose. The abstract does not name a primary outcome.
Other-product reference: this trial tested EMIQ, a separate product with its own page, not plain isoquercitrin. Randomized, placebo-controlled, double-blind parallel trial, registered retrospectively (UMIN000036036): 20 g whey with 42 mg EMIQ or whey alone after exercise, 6 days a week for 4 months, body composition by DXA; stated primary outcomes were changes in lean mass and lower limb muscle mass; supported by Morinaga & Co., which prepared the supplements, and four of seven authors (Nishimura, Tsukamoto, Maruki-Uchida, Morita) were Morinaga employees (Omi et al. 2019, J Int Soc Sports Nutr)
39 Japanese male university American football players randomized (19 EMIQ with whey, 20 whey alone), average age 19.8; one of 40 recruits was excluded before randomization.
Of the two stated primary outcomes, lower limb muscle mass rose more with EMIQ (about 931 g versus 256 g; p = 0.021), while whole-body lean mass did not differ; no correction for two primaries was reported, though p = 0.021 would still pass a two-outcome Bonferroni threshold of 0.025. Lower limb fat-free mass (p = 0.031) and the BAP/d-ROMs antioxidant ratio (p = 0.028) were higher, and body mass, fat mass and lower limb fat mass did not differ. No adverse events were linked to the product.
Other-product reference: this trial tested quercetin glycosides enzymatically made from isoquercitrin by San-Ei Gen F.F.I., the EMIQ maker, not plain isoquercitrin; see the EMIQ page. Randomized, double-blind, placebo-controlled trial (UMIN000053019): 200 mg/day quercetin glycosides or placebo during 6 weeks of resistance training; knee extensor force was the primary outcome; funded by a JSPS grant, and the authors declare no conflicts of interest (Nishikawa et al. 2025, Eur J Nutr)
30 healthy older adults in Japan were randomized (15 per group) and 26 completed.
Knee extensor force rose in both groups, more with quercetin glycosides (115.1% vs 105.3% of baseline; P < 0.001). Muscle mass did not change in either group. Firing rates of higher-threshold motor units were higher with the supplement. A small, short trial.
Other-product reference: this trial tested quercetin glycosides enzymatically made from isoquercitrin by San-Ei Gen F.F.I., the EMIQ maker, not plain isoquercitrin; see the EMIQ page. Randomized, controlled trial (UMIN000037633) of placebo or 200 or 500 mg/day quercetin glycosides with low-intensity resistance training 3 days a week for 24 weeks; funded by Suntory Wellness, with four employee authors (Otsuka et al. 2022, Front Nutr)
Community-dwelling Japanese adults aged 50 to 74; 48 completed the 24 weeks.
There was no difference in thigh muscle cross-sectional area, the primary outcome, or in lean mass. Thigh muscle stiffness in a stretched position was lower in both supplement groups than with placebo (P < 0.05), a secondary outcome.
Other-product reference: the drinks contained EMIQ (San-Ei Gen F.F.I.), standardized as isoquercitrin, not plain isoquercitrin; see the EMIQ page. Randomized, double-blind, placebo-controlled parallel-group trial: 500 mL a day of a drink with 110 mg quercetin glycosides (as isoquercitrin) or a matching drink for 40 weeks; MMSE total score was the primary endpoint; test drinks supplied by Suntory Beverage & Food, three of five authors at the Suntory research institute; the paper reports no external funding and no conflicts of interest (Nakamura et al. 2022, Eur Rev Med Pharmacol Sci)
80 healthy men and women aged 60 to 75 without cognitive impairment who noticed age-related forgetfulness; 71 completed and 68 were analyzed for efficacy.
MMSE total scores, the primary endpoint, rose in both groups with no difference between them. Reaction time on the Cognitrax battery improved more with the EMIQ drink than with placebo, while the overall Cognitrax index did not differ between groups. Brain blood volume, blood flow and activity measures did not differ significantly. Frequent urination was judged possibly related to the extra fluid.
Randomized, double-blind, placebo-controlled trial (NCT04514510) run at the US National Institutes of Health and sponsored by the NHLBI intramural research program: 1,000 mg isoquercetin (Quercis Pharma capsules that also contained vitamin C and niacin) once daily or a placebo with the same vitamin C and niacin, for 28 to 35 days; the primary outcome was the change in plasma soluble P-selectin; the authors declare no competing financial interests (Lizarralde-Iragorri et al. 2024, Blood Adv)
46 adults with steady-state sickle cell disease (23 per group), 75% taking hydroxyurea.
Soluble P-selectin, the primary outcome, did not differ between isoquercetin and placebo (P = .64). Within the isoquercetin group, whole-blood clotting and collagen-induced platelet aggregation fell from baseline. The authors described isoquercetin as well tolerated, with none of the recorded adverse events attributed to it and no off-target bleeding.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Isoquercitrin (Isoquercetin, Quercetin-3-O-glucoside)
How is isoquercitrin different from quercetin and EMIQ?
Plain quercetin has no sugar attached and dissolves poorly. Isoquercitrin (isoquercetin) is quercetin with one glucose, and EMIQ is isoquercitrin with a short chain of extra glucose units. In human absorption studies, EMIQ gave about twice the blood quercetin of isoquercitrin and about 20 times that of plain quercetin powder.
What is the recommended dosage of Isoquercitrin?
Studies of plain isoquercitrin used single doses of 50 to 400 mg for artery tests, and 500 to 1,000 mg a day of isoquercetin only in medically supervised patient studies. Trials of the related product EMIQ used 42 mg a day with protein powder and 100 mg EMIQ a day during pollen season. Follow the product label and ask a healthcare provider for personal advice.
Do the pollen season results apply to plain isoquercitrin?
Not directly. The two small Japanese trials that found lower eye symptom scores during cedar pollen season tested EMIQ, a related product with extra glucose units, five co-authors were from its maker, and nose symptoms did not differ significantly. No pollen season trial of plain isoquercitrin is cited here. Seasonal symptoms that affect daily life are worth discussing with a doctor.
Is Isoquercitrin safe, and does it have side effects?
In a placebo-controlled patient trial, the authors described 1,000 mg a day of isoquercetin for about 4 weeks as well tolerated, with no adverse events attributed to it, but long-term data are lacking. At high doses it lowered blood clotting markers, so check with your doctor if you take blood thinners, are pregnant or breastfeeding, or have surgery planned.
What is Isoquercitrin?
Isoquercitrin, also sold as isoquercetin, is quercetin with one glucose attached (quercetin-3-O-glucoside). For supplements it is made from rutin by removing one of its sugars.
What is Isoquercitrin used for?
NutraSmarts does not list Isoquercitrin under a health category. What the research covers: In 9 healthy adults, a single dose of pure isoquercitrin was absorbed quickly, with blood quercetin peaking about 37 minutes later.
Does Isoquercitrin interact with any medications?
Possible interactions include: Blood thinners and antiplatelet drugs (such as warfarin, aspirin and clopidogrel): isoquercetin lowered clotting and platelet activity markers in patient studies, so combining could add to their effect. Ask your doctor first. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Isoquercitrin?
NutraSmarts rates the evidence for Isoquercitrin as Preliminary (1 out of 5). It is backed by 9 study summaries and 17 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(17 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- Enzymatically modified isoquercitrin improves endothelial function in volunteers at risk of cardiovascular disease. Br J Nutr. 2020;123(2):182-189. doi: 10.1017/S0007114519002137.PubMedUsed to support: Other product (EMIQ). Randomized controlled crossover trial (ACTRN12617001202358) in 25 adults with at least one cardiovascular risk factor. A single dose of EMIQ prepared by San-Ei Gen F.F.I. (4.89 mg per kg body weight, 2 mg quercetin equivalent per kg) with a standard breakfast gave flow-mediated dilation, the primary endpoint, 1.80 percentage points higher than placebo (95% CI 0.23 to 3.37; P = 0.025) and higher plasma quercetin metabolites. Blood pressure, arterial stiffness, cognitive function and biochemical markers did not change. Funded by San-Ei Gen F.F.I., which the authors say had no role in design, analysis or writing; the authors declare no conflicts of interest.
- Acute effects of quercetin-3-O-glucoside on endothelial function and blood pressure: a randomized dose-response study. Am J Clin Nutr. 2016;104(1):97-103. doi: 10.3945/ajcn.116.131268.PubMedUsed to support: Randomized controlled crossover study in 15 healthy adults: single doses of 50 to 400 mg quercetin-3-O-glucoside raised blood quercetin with dose but did not improve flow-mediated dilation or blood pressure or change nitric oxide markers.
- Effect of enzymatically modified isoquercitrin, a flavonoid, on symptoms of Japanese cedar pollinosis: a randomized double-blind placebo-controlled trial. Int Arch Allergy Immunol. 2009;149(4):359-68. doi: 10.1159/000205582.PubMedUsed to support: Other product (EMIQ). Randomized double-blind placebo-controlled parallel trial in 20 adults with Japanese cedar pollen allergy who took EMIQ (two capsules daily of 100 mg, as the abstract words it) or placebo for 8 weeks of pollen season. Over the whole study, total eye symptom and eye itching scores were lower with EMIQ (p < 0.05); total symptom score was lower only in weeks 4 to 5, and nasal, eye congestion and daily activity scores only trended lower. Serum IgE and cytokines were not significantly lowered, while oxidized LDL and the chemokine TARC fell. The publisher's page lists five authors (Koyanagi, Kai, Shimizu, Moriwaki, Suzuki) at San-Ei-Gen F.F.I.
- Preventative effect of a flavonoid, enzymatically modified isoquercitrin on ocular symptoms of Japanese cedar pollinosis. Allergol Int. 2009;58(3):373-82. doi: 10.2332/allergolint.08-OA-0070.PubMedUsed to support: Other product (EMIQ). Randomized double-blind placebo-controlled parallel trial in 24 adults with Japanese cedar pollen allergy: 100 mg EMIQ or placebo for 8 weeks, starting 4 weeks before pollen release. Over the whole study, the eye symptom plus medication score was lower with EMIQ (p < 0.05), and eye symptom and eye congestion scores were lower in weeks 5 to 6; eye itching and tearing only trended lower. Nasal symptoms did not differ, IgE was not significantly lowered, and blood quercetin and its derivatives rose. Nearly the same author list as the in-season trial, including its five San-Ei-Gen co-authors.
- Effects of enzymatically modified isoquercitrin in supplementary protein powder on athlete body composition: a randomized, placebo-controlled, double-blind trial. J Int Soc Sports Nutr. 2019;16(1):39. doi: 10.1186/s12970-019-0303-x.PubMedUsed to support: Other product (EMIQ). Randomized double-blind parallel trial (UMIN000036036, registered retrospectively) in 39 male university American football players: 20 g whey with 42 mg EMIQ or whey alone, 6 days a week for 4 months. The stated primary outcomes were changes in lean mass and lower limb muscle mass: lower limb muscle mass rose more with EMIQ (mean change about 931 g versus 256 g; p = 0.021) while lean body mass did not differ. Lower limb fat-free mass and the BAP/d-ROMs antioxidant ratio were also higher; body mass and fat mass did not differ. No adverse events were linked to the product. Supported by Morinaga & Co., which prepared the supplements and employed four of the seven authors. A typesetting error in Table 3 was corrected later (PMID 31639004).
- Enzymatically modified isoquercitrin in soy protein temporarily enhanced the plasma amino-acid concentrations, antioxidant index, and plasma hormone levels: a randomized, double-blind cross-over trial. Amino Acids. 2023;55(6):769-776. doi: 10.1007/s00726-023-03267-4.PubMedUsed to support: Other product (EMIQ). Randomized double-blind crossover trial (UMIN000044791) in 9 healthy adults taking soy protein with or without 42 mg EMIQ for 7 days after mild exercise. Total plasma amino acids were higher with EMIQ at 0 and 120 minutes and easily oxidized amino acids at 120 minutes; oxidative stress readings were lower and plasma testosterone higher. Five of the nine authors were at the R&D Institute of Morinaga & Co.
- Effects of Quercetin Glycoside Supplementation Combined With Low-Intensity Resistance Training on Muscle Quantity and Stiffness: A Randomized, Controlled Trial. Front Nutr. 2022;9:912217. doi: 10.3389/fnut.2022.912217.PubMedUsed to support: Related San-Ei Gen material: quercetin glycosides enzymatically manufactured at San-Ei Gen F.F.I. from isoquercitrin, not named EMIQ in the paper. Randomized controlled trial (UMIN000037633) in Japanese adults aged 50 to 74 doing low-intensity resistance training 3 days a week for 24 weeks with placebo or 200 or 500 mg/day: thigh muscle cross-sectional area, the primary outcome, and lean mass did not differ between groups (48 completed); vastus lateralis stiffness in a stretched position was lower in both supplement groups. No side effects were attributed to the supplement. Funded by Suntory Wellness, with four employee authors.
- Quercetin ingestion alters motor unit behavior and enhances improvement in muscle strength following resistance training in older adults: a randomized, double-blind, controlled trial. Eur J Nutr. 2025;64(3):117. doi: 10.1007/s00394-025-03634-9.PubMedUsed to support: Related San-Ei Gen material: the methods state the quercetin glycosides were enzymatically manufactured at San-Ei Gen F.F.I. from isoquercitrin, but the paper does not use the EMIQ name. Randomized double-blind trial (UMIN000053019): 30 older adults were randomized and 26 completed 6 weeks of resistance training with 200 mg/day quercetin glycosides or placebo. Knee extensor force, the primary outcome, rose more with quercetin glycosides (115.1% versus 105.3% of baseline; p < 0.001), muscle mass did not change in either group, and firing rates of higher-threshold motor units were higher. Funded by a JSPS grant; the authors declare no conflicts of interest.
- Effect of quercetin glycosides on cognitive functions and cerebral blood flow: a randomized, double-blind, and placebo-controlled study. Eur Rev Med Pharmacol Sci. 2022;26(23):8700-8712. doi: 10.26355/eurrev_202212_30541.PubMedUsed to support: Other product (EMIQ): the full text states the drinks contained enzymatically modified quercetin (EMIQ, San-Ei Gen F.F.I.), standardized as isoquercitrin. Randomized double-blind placebo-controlled trial in 80 healthy adults aged 60 to 75 (68 analyzed): a drink with 110 mg quercetin glycosides daily for 40 weeks did not change MMSE total score, the primary endpoint, versus placebo; reaction time on the Cognitrax battery improved versus placebo, and cerebral blood flow measures did not differ significantly. Test drinks supplied by Suntory Beverage & Food; three of five authors at the Suntory research institute; no external funding stated.
- alpha-Oligoglucosylation of a sugar moiety enhances the bioavailability of quercetin glucosides in humans. Arch Biochem Biophys. 2010;501(1):91-7. doi: 10.1016/j.abb.2010.06.036.PubMedUsed to support: Human absorption study: EMIQ, made from rutin by enzymes, raised plasma quercetin metabolites quickly and was absorbed more efficiently than isoquercitrin or rutin, with the same profile of plasma metabolites as isoquercitrin.
- Bioavailabilities of quercetin-3-glucoside and quercetin-4'-glucoside do not differ in humans. J Nutr. 2000;130(5):1200-3. doi: 10.1093/jn/130.5.1200.PubMedUsed to support: Single-dose study in 9 healthy adults: pure quercetin-3-glucoside (isoquercitrin) was absorbed as well as quercetin-4'-glucoside, with blood quercetin peaking at about 5.0 micromol/L about 37 minutes after intake and an elimination half-life of about 18.5 hours.
- Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies. Food Chem. 2025;477:143630. doi: 10.1016/j.foodchem.2025.143630.PubMedUsed to support: Systematic review and meta-analysis of 31 human studies: quercetin-3-O-oligoglucosides (the EMIQ type) gave about 2-fold the bioavailability of quercetin-3-O-glucoside, about 10-fold that of rutin and about 20-fold that of quercetin aglycone; the lecithin phytosome showed a 20.1-fold increase versus aglycone.
- Quercetin from shallots (Allium cepa L. var. aggregatum) is more bioavailable than its glucosides. J Nutr. 2008;138(5):885-8. doi: 10.1093/jn/138.5.885.PubMedUsed to support: Randomized crossover study in 9 volunteers: quercetin from dry shallot skin, mostly the aglycone dispersed in a food matrix, gave higher blood quercetin than shallot flesh rich in quercetin glucosides, showing that the food matrix also affects absorption.
- Isoquercetin for thromboinflammation in sickle cell disease: a randomized double-blind placebo-controlled trial. Blood Adv. 2024;8(1):172-182. doi: 10.1182/bloodadvances.2023011542.PubMedUsed to support: Randomized double-blind placebo-controlled trial in 46 adults with sickle cell disease: 1,000 mg/day isoquercetin for about 4 weeks did not change soluble P-selectin, the primary outcome, versus placebo. Whole-blood coagulation and platelet aggregation fell from baseline in the isoquercetin group; the authors describe it as well tolerated, and adverse events were not attributed to it. No competing financial interests declared.
- Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019;4(4):e125851. doi: 10.1172/jci.insight.125851.PubMedUsed to support: Phase 2 study in patients with advanced cancer: isoquercetin at 500 or 1,000 mg/day for 56 days lowered platelet-dependent thrombin generation, and at 1,000 mg/day lowered D-dimer by a median 21.9%; no major bleeding was seen. Funded in part by Quercegen Pharmaceuticals; no placebo group.
- GRAS Notice GRN 220: alpha-Glycosyl isoquercitrin (notifier San-Ei Gen F.F.I., Inc.). FDA GRAS Notice Inventory. 2007;FDA response dated November 19, 2007: FDA has no questions..SourceUsed to support: Not PubMed-indexed; official FDA inventory entry, read 2026. San-Ei Gen F.F.I., Inc. (Toyonaka, Osaka) notified alpha-glycosyl isoquercitrin as generally recognized as safe for use as an antioxidant in multiple food categories at 150 mg/kg and in chewing gum at 1,500 mg/kg; FDA had no questions. The notice covers food use, not supplement doses.
- Safety Aspects of the Use of Quercetin as a Dietary Supplement. Mol Nutr Food Res. 2018;62(1). doi: 10.1002/mnfr.201700447.PubMedUsed to support: Review by the German Federal Institute for Risk Assessment of isolated quercetin as a dietary supplement: adverse effects in human intervention studies were rarely reported and mild; adequate data on long-term use (more than 12 weeks) of 1,000 mg a day or more are not available; animal studies suggest possible worsening of damage in a predamaged kidney and promotion of estrogen-dependent tumors; animal and human studies of single or short-term quercetin use found interactions that altered drug bioavailability.